Merck (NYSE: MRK) announced the publication of research detailing a large-scale synthesis method for enlicitide decanoate, its investigational oral PCSK9 inhibitor, in the journal Science.

The publication describes a biocatalytic process using enzymes to manufacture the macrocyclic peptide compound. Merck scientists outlined how the method employs enzymes for peptide fragment formation, coupling, and macrocyclization, combined with crystallization purification techniques.

Enlicitide is designed as an oral PCSK9 inhibitor that would lower LDL cholesterol through the same biological mechanism as currently approved injectable PCSK9 inhibitors. The compound binds to PCSK9 and blocks its interaction with LDL receptors, potentially increasing the number of receptors available to remove LDL cholesterol from blood.

"Macrocyclic peptides have the potential to unlock new opportunities to develop oral treatment options for challenging therapeutic targets and broaden patient access," said Dr. Dean Y. Li, president of Merck Research Laboratories.

PCSK9 inhibitors currently on the market are administered by injection. Enlicitide represents an attempt to create an oral version of this cholesterol-lowering therapy.

The synthesis method described uses biocatalysis, a process employing enzymes for chemical synthesis. Merck stated it has invested in biocatalysis development for over 25 years.

Macrocyclic peptides are ring-shaped molecules designed to target protein-protein interactions while maintaining oral bioavailability. The compounds aim to provide the potency and selectivity of biologic therapies in pill form.

The information is based on a company press release statement.